Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DNA X, Inc. filings document the company's shift from Sonim Technologies to a cryptocurrency trading-services business, including the acquisition of DNA X LLC, the completed sale of mobile device assets, and the January 2026 corporate rebrand while the Nasdaq ticker remained SONM.
The filing record includes Current Reports on Form 8-K and related amendments covering material agreements, convertible-note financing, common-stock issuance, operating results, shareholder voting matters, executive departures and compensation arrangements, and auditor changes. Other disclosures address late annual-report notification, internal-control weakness, going-concern language, capital structure, risk factors, and financial-reporting obligations.
DNA X, Inc. terminated its financing arrangements with Chardan Capital Markets LLC that had allowed Chardan to purchase up to $500 million of DNA X common stock. These arrangements consisted of a ChEF Purchase Agreement and a related Registration Rights Agreement.
The termination was effected by letter agreement and became effective as of 5:00 p.m. New York City time on May 28, 2026. These agreements had previously given Chardan the ability to buy shares over time and required DNA X to register those shares for resale.
DNA X, Inc. entered a Securities Purchase Agreement with DNA Holdings Venture, Inc. and issued a secured convertible promissory note with principal of $3,052,787.68. The company received $1,800,000.00 in cash and cancelled a prior $1,200,000.00 note plus accrued interest.
The new note matures on December 31, 2026, bears 10% annual interest, and is convertible into common stock at $6.00 per share, subject to stockholder approval and adjustment. Proceeds must be used for working capital, excluding repayment of most debt, equity redemptions, or litigation settlements.
The company also amended a Membership Interest Purchase Agreement to terminate a put option and secured the note with a first-priority lien on its ownership interests in DNA X, LLC. Separately, Nasdaq staff issued a delisting determination after the company reported a stockholders’ deficit of $983,000 versus the $2,500,000 stockholders’ equity requirement. DNA X plans to request a hearing, but there is no assurance it will regain or maintain Nasdaq listing compliance.
DNA X, Inc. (formerly Sonim Technologies) has completed a major strategic shift and now focuses on its DNA X AI and crypto trading platform after selling its legacy phone and hotspot business. The January 23, 2026 asset sale generated a pre-tax gain of $15,563 thousand and net income from discontinued operations of $10,268 thousand for the quarter, driving total net income to $6,340 thousand despite no revenue from continuing operations and a continuing-operations net loss of $3,928 thousand.
Total assets dropped to $4,838 thousand at March 31, 2026 from $43,898 thousand after removing the disposed business, while stockholders’ deficit narrowed to $983 thousand. Cash and cash equivalents were $1,195 thousand, and the company carries a related-party convertible note with a principal of $1,200 thousand plus a derivative liability of $398 thousand tied to its conversion features.
On May 20, 2026, DNA X issued a new related-party convertible promissory note with a principal balance of $3,053 thousand, receiving $1,800 thousand in cash and cancelling the prior note and accrued interest. Management states these proceeds are expected to fund operation of the AI and crypto platform through December 31, 2026, but also discloses substantial doubt about the company’s ability to continue as a going concern if the note is not converted or additional financing is not obtained.
DNA X, Inc. reported first-quarter 2026 results that reflect its exit from the legacy mobile device business and pivot to an AI-driven crypto trading platform. The company sold its mobile device design and manufacturing assets to NEXA for $15 million, less a $1.5 million working capital adjustment, generating $6.3 million in net income from the sale.
From continuing operations, DNA X recorded a $3.9 million net loss as it invested in the DNA X AI trading platform, while revenue from phones and hotspots is now reported in discontinued operations. Cash was $1.2 million at March 31, 2026, and the company agreed to raise an additional $1.8 million through new debt to fund working capital and support growth of the AI and crypto trading business.
DNA X, Inc. notified the SEC that it could not timely file its Form 10-Q for the three months ended March 31, 2026. The delay stems from the disposition of the company’s Legacy Business and the required discontinued operations accounting under ASC 205-20, which requires separating current results, retrospectively recasting prior periods, and computing the gain or loss on disposition and related income-tax allocation.
The company says the accounting complexity and the need for accurate retrospective adjustments have extended the financial close. DNA X expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date and anticipates reporting $3.6 million net loss from continuing operations for the three months ended March 31, 2026, compared to $0.7 million net loss for the three months ended March 31, 2025.
DNA X, Inc. ownership filing: Laurence W. Lytton reports beneficial ownership of 120,357 shares of Common Stock, representing 8.1% of the class. The percentage is calculated based on 1,488,268 shares outstanding as of April 21, 2026. The filing notes that this total excludes warrants to purchase 22,222 shares that are subject to a 4.99% beneficial ownership limitation.
DNA X, Inc. filed Amendment No. 1 to its annual report to update Part III disclosures on directors, executive compensation, security ownership, related‑party transactions, and auditor fees, and to add certain exhibits and officer certifications.
The filing details leadership changes, including the former CEO’s resignation and a cash severance of $855,000, plus accelerated option vesting and COBRA coverage. It also outlines a membership interest purchase from DNA Holdings for 223,201 redeemable shares, and a related unsecured $1,200,000 note bearing 10% interest, convertible into common stock at an initial price of $5.50 per share, with protective adjustments. As of April 21, 2026, there were 1,488,268 shares outstanding, and the aggregate market value of non‑affiliate shares was about $12.6 million as of June 30, 2025.
DNA X, Inc. filed an 8-K announcing that its Audit Committee dismissed Baker Tilly US, LLP as independent registered public accounting firm and approved the engagement of TAAD LLP for the fiscal year ending December 31, 2026.
Baker Tilly’s reports on the 2024 and 2025 financial statements were generally unqualified but the 2025 report included a statement raising substantial doubt about the company’s ability to continue as a going concern. The company also disclosed a continuing material weakness in internal control over financial reporting related to insufficient technical accounting expertise for complex, non-routine transactions, which has not yet been remediated.
The company reported no disagreements with Baker Tilly on accounting, disclosure, or audit scope, and no other reportable events beyond the previously disclosed material weakness. Baker Tilly provided a letter to the SEC agreeing with the company’s description of these matters, filed as Exhibit 16.1.
DNA X, Inc. (formerly Sonim Technologies) files its annual report describing its pivot from rugged mobile devices to a crypto trading platform operating at www.dnax.us. The company now focuses on automated cryptocurrency trading, swapping and planned products such as crypto lending and staking-like fee products.
The filing highlights intense competition with much larger exchanges, heavy reliance on third‑party contractors and a highly uncertain, fast‑evolving regulatory landscape for digital assets in the U.S. and abroad. DNA X is not yet profitable, and its auditor raises substantial doubt about its ability to continue as a going concern without additional funding.
The report emphasizes significant risks from cryptocurrency price volatility, potential classification of certain tokens or staking services as securities, and complex privacy, sanctions, consumer protection and anti‑money‑laundering rules. As of June 30, 2025, non‑affiliate equity market value was about $12.6 million, and 1,488,268 common shares were outstanding as of March 27, 2026.
DNA X, Inc. reported full-year 2025 results showing a net loss of $20.7 million, improved from $33.6 million in 2024, with no revenue from continuing operations. Continuing-operations net loss was $8.0 million, driven mainly by $5.4 million in general and administrative expenses and higher interest and other expenses.
The company completed its strategic pivot from mobile devices to cryptocurrency trading. It acquired the DNA X trading platform in December 2025 and sold its mobile device design and manufacturing business to NEXA for $15 million in January 2026. Most proceeds repaid debt and other obligations, with remaining cash earmarked to support the trading business.
As of December 31, 2025, cash and cash equivalents were $1.3 million, total assets $43.9 million, total liabilities $50.6 million, and stockholders’ deficit $8.0 million. The company rebranded to DNA X, Inc., operates a DeFi-based automated trading platform, and experienced leadership changes, including the CEO’s resignation and appointment of its Executive Chairman as acting CEO.